25 XP   0   0   10

Daewon Pharm
Buy, Hold or Sell?

Let's analyse Daewon Pharm together

PenkeI guess you are interested in Daewon Pharm. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Daewon Pharm. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Daewon Pharm

I send you an email if I find something interesting about Daewon Pharm.

Quick analysis of Daewon Pharm (30 sec.)










What can you expect buying and holding a share of Daewon Pharm? (30 sec.)

How much money do you get?

How much money do you get?
₩0.48
When do you have the money?
1 year
How often do you get paid?
80.0%

What is your share worth?

Current worth
₩12,467.63
Expected worth in 1 year
₩13,198.83
How sure are you?
92.5%

+ What do you gain per year?

Total Gains per Share
₩1,423.76
Return On Investment
9.4%

For what price can you sell your share?

Current Price per Share
₩15,070.00
Expected price per share
₩13,530 - ₩16,100
How sure are you?
50%

1. Valuation of Daewon Pharm (5 min.)




Live pricePrice per Share (EOD)

₩15,070.00

Intrinsic Value Per Share

₩12,173.45 - ₩60,874.91

Total Value Per Share

₩24,641.08 - ₩73,342.53

2. Growth of Daewon Pharm (5 min.)




Is Daewon Pharm growing?

Current yearPrevious yearGrowGrow %
How rich?$184.9m$164.8m$16.6m9.2%

How much money is Daewon Pharm making?

Current yearPrevious yearGrowGrow %
Making money$4.1m$5.5m-$1.4m-33.6%
Net Profit Margin4.6%6.7%--

How much money comes from the company's main activities?

3. Financial Health of Daewon Pharm (5 min.)




What can you expect buying and holding a share of Daewon Pharm? (5 min.)

Welcome investor! Daewon Pharm's management wants to use your money to grow the business. In return you get a share of Daewon Pharm.

What can you expect buying and holding a share of Daewon Pharm?

First you should know what it really means to hold a share of Daewon Pharm. And how you can make/lose money.

Speculation

The Price per Share of Daewon Pharm is ₩15,070. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Daewon Pharm.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Daewon Pharm, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ₩12,467.63. Based on the TTM, the Book Value Change Per Share is ₩182.80 per quarter. Based on the YOY, the Book Value Change Per Share is ₩360.83 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ₩173.14 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Daewon Pharm.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps0.020.0%0.180.0%0.310.0%0.150.0%0.130.0%
Usd Book Value Change Per Share0.020.0%0.130.0%0.250.0%0.430.0%0.120.0%
Usd Dividend Per Share0.000.0%0.120.0%0.190.0%0.110.0%0.080.0%
Usd Total Gains Per Share0.020.0%0.250.0%0.440.0%0.550.0%0.200.0%
Usd Price Per Share10.96-10.60-11.81-11.82-12.57-
Price to Earnings Ratio110.72-36.33-9.95-214.41-192.86-
Price-to-Total Gains Ratio515.01-159.05-28.50-742.59-1,281.15-
Price to Book Ratio1.26-1.24-1.52-27.03-43.62-
Price-to-Total Gains Ratio515.01-159.05-28.50-742.59-1,281.15-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share10.549
Number of shares94
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.120.11
Usd Book Value Change Per Share0.130.43
Usd Total Gains Per Share0.250.55
Gains per Quarter (94 shares)23.4251.36
Gains per Year (94 shares)93.68205.43
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
146488443163195
2919617885326400
3137144272128489605
4182192366170651810
52282414602138141015
62732895542559771220
731933764829811401425
836538574234113031630
941043383638314661835
1045648193042616292040

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%11.01.00.091.7%19.01.00.095.0%38.02.00.095.0%42.02.00.095.5%
Book Value Change Per Share4.00.00.0100.0%11.01.00.091.7%19.01.00.095.0%35.05.00.087.5%39.05.00.088.6%
Dividend per Share2.00.02.050.0%10.00.02.083.3%16.00.04.080.0%32.00.08.080.0%35.00.09.079.5%
Total Gains per Share4.00.00.0100.0%11.01.00.091.7%19.01.00.095.0%37.03.00.092.5%41.03.00.093.2%

Fundamentals of Daewon Pharm

About Daewon Pharm

Daewon Pharmaceutical Co., Ltd., a pharmaceutical company, manufactures and sells medicines and medical supplies in South Korea. It offers various medicines for circulatory, respiratory, antibiotic, chemotherapy, and psychoneurosis use. The company's principal products include Oramin-F Soft Cap, a multivitamin product; Pelubi Tablet, a NSAID product for pain relief; Freefol-MCT Inj., a microemulsion propofol for the anti-exogenous infectious bacteria; Megex-I Susp, a medicine that supplements subalimentation of cancer patients; Trigel Susp, a therapy for gastritis and duodenal ulcer; and Renamezin Cap, a spherical carbonaceous adsorbent for chronic kidney disease. It also exports its products to approximately 40 countries primarily in Asia, Central and South America, the Middle East, CIS, and Africa. The company was founded in 1958 and is headquartered in Seoul, South Korea.

Fundamental data was last updated by Penke on 2024-04-14 20:34:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating less efficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is just able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is underpriced.
Based on the earnings, the company is overpriced.
Based on how much money comes from the company's main activities, the company is cheap.

1.1. Profitability of Daewon Pharm.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Daewon Pharm earns for each ₩1 of revenue.

  • Above 10% is considered healthy but always compare Daewon Pharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 0.5% means that ₩0.01 for each ₩1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Daewon Pharm:

  • The MRQ is 0.5%. The company is not making a profit/loss.
  • The TTM is 4.6%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ0.5%TTM4.6%-4.1%
TTM4.6%YOY6.7%-2.0%
TTM4.6%5Y5.4%-0.7%
5Y5.4%10Y6.5%-1.1%
1.1.2. Return on Assets

Shows how efficient Daewon Pharm is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Daewon Pharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • 0.1% Return on Assets means that Daewon Pharm generated ₩0.00 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Daewon Pharm:

  • The MRQ is 0.1%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is 1.3%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ0.1%TTM1.3%-1.1%
TTM1.3%YOY1.8%-0.5%
TTM1.3%5Y1.4%-0.1%
5Y1.4%10Y1.8%-0.4%
1.1.3. Return on Equity

Shows how efficient Daewon Pharm is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Daewon Pharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • 0.3% Return on Equity means Daewon Pharm generated ₩0.00 for each ₩1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Daewon Pharm:

  • The MRQ is 0.3%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 2.3%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ0.3%TTM2.3%-2.0%
TTM2.3%YOY3.4%-1.1%
TTM2.3%5Y2.4%-0.1%
5Y2.4%10Y2.6%-0.2%

1.2. Operating Efficiency of Daewon Pharm.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Daewon Pharm is operating .

  • Measures how much profit Daewon Pharm makes for each ₩1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Daewon Pharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated ₩0.00  for each ₩1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Daewon Pharm:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM3.7%-3.7%
TTM3.7%YOY8.1%-4.4%
TTM3.7%5Y8.1%-4.4%
5Y8.1%10Y6.4%+1.7%
1.2.2. Operating Ratio

Measures how efficient Daewon Pharm is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.45 means that the operating costs are ₩1.45 for each ₩1 in net sales.

Let's take a look of the Operating Ratio trends of Daewon Pharm:

  • The MRQ is 1.453. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.346. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.453TTM1.346+0.107
TTM1.346YOY1.319+0.027
TTM1.3465Y1.294+0.052
5Y1.29410Y1.057+0.237

1.3. Liquidity of Daewon Pharm.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Daewon Pharm is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 1.15 means the company has ₩1.15 in assets for each ₩1 in short-term debts.

Let's take a look of the Current Ratio trends of Daewon Pharm:

  • The MRQ is 1.146. The company is just able to pay all its short-term debts.
  • The TTM is 1.490. The company is just able to pay all its short-term debts.
Trends
Current periodCompared to+/- 
MRQ1.146TTM1.490-0.344
TTM1.490YOY1.705-0.216
TTM1.4905Y1.777-0.287
5Y1.77710Y1.402+0.374
1.3.2. Quick Ratio

Measures if Daewon Pharm is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Daewon Pharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 0.39 means the company can pay off ₩0.39 for each ₩1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Daewon Pharm:

  • The MRQ is 0.387. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.628. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.387TTM0.628-0.242
TTM0.628YOY0.832-0.204
TTM0.6285Y0.769-0.141
5Y0.76910Y0.899-0.130

1.4. Solvency of Daewon Pharm.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Daewon Pharm assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Daewon Pharm to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.48 means that Daewon Pharm assets are financed with 48.0% credit (debt) and the remaining percentage (100% - 48.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Daewon Pharm:

  • The MRQ is 0.480. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.454. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.480TTM0.454+0.026
TTM0.454YOY0.482-0.029
TTM0.4545Y0.429+0.024
5Y0.42910Y0.344+0.085
1.4.2. Debt to Equity Ratio

Measures if Daewon Pharm is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Daewon Pharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 91.6% means that company has ₩0.92 debt for each ₩1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Daewon Pharm:

  • The MRQ is 0.916. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.825. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.916TTM0.825+0.091
TTM0.825YOY0.928-0.103
TTM0.8255Y0.762+0.063
5Y0.76210Y0.558+0.204

2. Market Valuation of Daewon Pharm

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₩1 in earnings Daewon Pharm generates.

  • Above 15 is considered overpriced but always compare Daewon Pharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 110.72 means the investor is paying ₩110.72 for every ₩1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Daewon Pharm:

  • The EOD is 106.552. Based on the earnings, the company is expensive. -2
  • The MRQ is 110.724. Based on the earnings, the company is expensive. -2
  • The TTM is 36.334. Based on the earnings, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD106.552MRQ110.724-4.172
MRQ110.724TTM36.334+74.390
TTM36.334YOY9.951+26.383
TTM36.3345Y214.414-178.080
5Y214.41410Y192.861+21.553
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Daewon Pharm:

  • The EOD is 5.073. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 5.272. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is 1.752. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD5.073MRQ5.272-0.199
MRQ5.272TTM1.752+3.520
TTM1.752YOY2.790-1.039
TTM1.7525Y-390.740+392.491
5Y-390.74010Y-636.624+245.884
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Daewon Pharm is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 1.26 means the investor is paying ₩1.26 for each ₩1 in book value.

Let's take a look of the Price to Book Ratio trends of Daewon Pharm:

  • The EOD is 1.209. Based on the equity, the company is underpriced. +1
  • The MRQ is 1.256. Based on the equity, the company is underpriced. +1
  • The TTM is 1.238. Based on the equity, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD1.209MRQ1.256-0.047
MRQ1.256TTM1.238+0.019
TTM1.238YOY1.521-0.284
TTM1.2385Y27.025-25.788
5Y27.02510Y43.620-16.595
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Daewon Pharm compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--30.407182.802-83%360.830-92%618.789-95%166.320-82%
Book Value Per Share--12467.62812234.210+2%11103.314+12%9109.503+37%7207.615+73%
Current Ratio--1.1461.490-23%1.705-33%1.777-36%1.402-18%
Debt To Asset Ratio--0.4800.454+6%0.482-1%0.429+12%0.344+39%
Debt To Equity Ratio--0.9160.825+11%0.928-1%0.762+20%0.558+64%
Dividend Per Share---173.138-100%270.187-100%161.718-100%116.751-100%
Eps--35.358263.785-87%436.824-92%219.015-84%188.879-81%
Free Cash Flow Per Share--742.668367.094+102%235.205+216%175.419+323%113.859+552%
Free Cash Flow To Equity Per Share--742.668146.231+408%-23.650+103%170.563+335%123.767+500%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--60874.906--------
Intrinsic Value_10Y_min--12173.448--------
Intrinsic Value_1Y_max--1716.100--------
Intrinsic Value_1Y_min--589.043--------
Intrinsic Value_3Y_max--8497.299--------
Intrinsic Value_3Y_min--2326.690--------
Intrinsic Value_5Y_max--19306.619--------
Intrinsic Value_5Y_min--4661.309--------
Market Cap319423720000.000-4%331930143000.000321066605750.000+3%357891890625.000-7%5180400331423.408-94%7546287343394.578-96%
Net Profit Margin--0.0050.046-89%0.067-92%0.054-90%0.065-92%
Operating Margin---0.037-100%0.081-100%0.081-100%0.064-100%
Operating Ratio--1.4531.346+8%1.319+10%1.294+12%1.057+37%
Pb Ratio1.209-4%1.2561.238+1%1.521-17%27.025-95%43.620-97%
Pe Ratio106.552-4%110.72436.334+205%9.951+1013%214.414-48%192.861-43%
Price Per Share15070.000-4%15660.00015147.500+3%16875.000-7%16892.475-7%17950.563-13%
Price To Free Cash Flow Ratio5.073-4%5.2721.752+201%2.790+89%-390.740+7512%-636.624+12177%
Price To Total Gains Ratio495.602-4%515.005159.048+224%28.499+1707%742.589-31%1281.149-60%
Quick Ratio--0.3870.628-38%0.832-54%0.769-50%0.899-57%
Return On Assets--0.0010.013-89%0.018-92%0.014-89%0.018-92%
Return On Equity--0.0030.023-88%0.034-92%0.024-88%0.026-89%
Total Gains Per Share--30.407355.940-91%631.018-95%780.508-96%283.071-89%
Usd Book Value--184985130.799181521528.176+2%164838128.457+12%154952810.955+19%131227519.860+41%
Usd Book Value Change Per Share--0.0210.128-83%0.253-92%0.433-95%0.116-82%
Usd Book Value Per Share--8.7278.564+2%7.772+12%6.377+37%5.045+73%
Usd Dividend Per Share---0.121-100%0.189-100%0.113-100%0.082-100%
Usd Eps--0.0250.185-87%0.306-92%0.153-84%0.132-81%
Usd Free Cash Flow--11019146.4675446653.767+102%3493151.097+215%2284712.893+382%1561138.250+606%
Usd Free Cash Flow Per Share--0.5200.257+102%0.165+216%0.123+323%0.080+552%
Usd Free Cash Flow To Equity Per Share--0.5200.102+408%-0.017+103%0.119+335%0.087+500%
Usd Market Cap223596604.000-4%232351100.100224746624.025+3%250524323.438-7%3626280231.996-94%5282401140.376-96%
Usd Price Per Share10.549-4%10.96210.603+3%11.813-7%11.825-7%12.565-13%
Usd Profit--524617.8424185462.960-87%5590261.318-91%3772280.727-86%3428799.127-85%
Usd Revenue--98597066.68792216607.917+7%83804814.816+18%69521960.152+42%55603636.807+77%
Usd Total Gains Per Share--0.0210.249-91%0.442-95%0.546-96%0.198-89%
 EOD+4 -4MRQTTM+13 -22YOY+14 -215Y+12 -2310Y+12 -23

3.2. Fundamental Score

Let's check the fundamental score of Daewon Pharm based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15106.552
Price to Book Ratio (EOD)Between0-11.209
Net Profit Margin (MRQ)Greater than00.005
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than10.387
Current Ratio (MRQ)Greater than11.146
Debt to Asset Ratio (MRQ)Less than10.480
Debt to Equity Ratio (MRQ)Less than10.916
Return on Equity (MRQ)Greater than0.150.003
Return on Assets (MRQ)Greater than0.050.001
Total4/10 (40.0%)

3.3. Technical Score

Let's check the technical score of Daewon Pharm based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5056.652
Ma 20Greater thanMa 5014,718.500
Ma 50Greater thanMa 10014,892.400
Ma 100Greater thanMa 20015,130.300
OpenGreater thanClose15,180.000
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in KRW. All numbers in thousands.

Summary
Total Assets507,998,342
Total Liabilities243,733,870
Total Stockholder Equity266,198,939
 As reported
Total Liabilities 243,733,870
Total Stockholder Equity+ 266,198,939
Total Assets = 507,998,342

Assets

Total Assets507,998,342
Total Current Assets209,293,035
Long-term Assets298,705,307
Total Current Assets
Cash And Cash Equivalents 29,982,403
Short-term Investments 47,709
Net Receivables 70,601,833
Inventory 105,078,000
Other Current Assets 0
Total Current Assets  (as reported)209,293,035
Total Current Assets  (calculated)205,709,945
+/- 3,583,090
Long-term Assets
Property Plant Equipment 160,091,814
Goodwill 7,254,091
Intangible Assets 34,217,539
Long-term Assets  (as reported)298,705,307
Long-term Assets  (calculated)201,563,444
+/- 97,141,864

Liabilities & Shareholders' Equity

Total Current Liabilities182,690,483
Long-term Liabilities61,043,387
Total Stockholder Equity266,198,939
Total Current Liabilities
Short Long Term Debt 109,453,855
Accounts payable 20,909,853
Other Current Liabilities 1
Total Current Liabilities  (as reported)182,690,483
Total Current Liabilities  (calculated)130,363,709
+/- 52,326,774
Long-term Liabilities
Long term Debt 34,574,760
Capital Lease Obligations Min Short Term Debt2,021,075
Long-term Liabilities Other 0
Long-term Liabilities  (as reported)61,043,387
Long-term Liabilities  (calculated)36,595,835
+/- 24,447,551
Total Stockholder Equity
Retained Earnings 255,790,157
Total Stockholder Equity (as reported)266,198,939
Total Stockholder Equity (calculated)255,790,157
+/- 10,408,781
Other
Capital Stock11,095,097
Common Stock Shares Outstanding 21,196
Net Debt 114,046,213
Net Invested Capital 410,227,554
Net Working Capital 26,602,552
Property Plant and Equipment Gross 275,141,236



Balance Sheet

Currency in KRW. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312018-12-312018-09-302018-06-302018-03-312017-12-312017-09-302017-06-302017-03-312016-12-312016-09-302016-06-302016-03-312015-12-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-31
> Total Assets 
148,808,030
154,964,506
156,926,287
160,139,939
166,021,057
166,051,015
172,504,874
180,616,842
185,893,985
183,035,100
185,519,197
194,749,289
198,958,334
203,432,375
204,962,201
214,681,777
218,059,266
221,426,212
230,260,999
227,202,070
240,800,034
244,323,273
252,195,122
275,438,692
294,334,591
303,291,531
311,602,346
327,532,233
329,086,818
324,051,880
333,210,203
335,214,010
345,726,625
391,153,962
418,570,198
429,579,922
449,072,605
453,688,584
463,370,124
453,550,066
455,886,245
458,619,067
478,547,202
507,998,342
507,998,342478,547,202458,619,067455,886,245453,550,066463,370,124453,688,584449,072,605429,579,922418,570,198391,153,962345,726,625335,214,010333,210,203324,051,880329,086,818327,532,233311,602,346303,291,531294,334,591275,438,692252,195,122244,323,273240,800,034227,202,070230,260,999221,426,212218,059,266214,681,777204,962,201203,432,375198,958,334194,749,289185,519,197183,035,100185,893,985180,616,842172,504,874166,051,015166,021,057160,139,939156,926,287154,964,506148,808,030
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
95,065,620
97,145,980
98,083,704
103,364,568
95,787,595
99,071,287
97,496,738
98,058,169
106,724,038
108,319,353
105,296,284
109,570,003
121,547,977
124,584,761
114,388,135
121,443,676
117,276,452
130,643,271
144,631,823
171,360,783
180,377,166
195,382,162
196,435,288
208,111,238
207,283,825
207,267,625
203,059,752
220,729,045
209,293,035
209,293,035220,729,045203,059,752207,267,625207,283,825208,111,238196,435,288195,382,162180,377,166171,360,783144,631,823130,643,271117,276,452121,443,676114,388,135124,584,761121,547,977109,570,003105,296,284108,319,353106,724,03898,058,16997,496,73899,071,28795,787,595103,364,56898,083,70497,145,98095,065,620000000000000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
13,978,828
13,015,457
11,298,985
7,735,067
3,677,068
10,623,289
12,724,159
9,857,449
14,887,430
11,492,721
12,905,891
12,700,534
13,003,908
14,309,121
7,116,967
8,260,750
10,439,087
7,659,789
13,256,175
8,636,179
41,697,121
9,522,373
16,660,911
13,396,095
26,969,832
7,103,419
15,837,217
11,835,183
29,982,403
29,982,40311,835,18315,837,2177,103,41926,969,83213,396,09516,660,9119,522,37341,697,1218,636,17913,256,1757,659,78910,439,0878,260,7507,116,96714,309,12113,003,90812,700,53412,905,89111,492,72114,887,4309,857,44912,724,15910,623,2893,677,0687,735,06711,298,98513,015,45713,978,828000000000000000
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
4,706,650
6,830,713
10,058,686
10,192,695
4,626,375
7,994,004
1,599,838
31,918
60,739
9,510,744
5,200,105
1,708,866
6,245,568
9,452,157
8,837,318
11,521,968
81,499
11,693,755
8,706,827
44,071,673
13,123,155
43,815,716
36,529,580
45,416,220
20,035,799
39,983,527
30,270,689
21,317,112
47,709
47,70921,317,11230,270,68939,983,52720,035,79945,416,22036,529,58043,815,71613,123,15544,071,6738,706,82711,693,75581,49911,521,9688,837,3189,452,1576,245,5681,708,8665,200,1059,510,74460,73931,9181,599,8387,994,0044,626,37510,192,69510,058,6866,830,7134,706,650000000000000000
       Net Receivables 
31,063,368
32,216,721
29,473,389
32,241,380
32,162,840
27,810,965
27,565,908
31,343,649
27,631,256
27,115,549
28,572,063
31,926,955
30,860,315
32,521,075
30,731,197
34,853,201
32,082,362
33,715,556
39,420,015
48,115,105
36,157,353
38,962,094
39,830,821
46,199,017
34,671,609
37,228,890
36,566,903
48,552,666
42,653,857
42,710,535
44,033,898
42,301,767
42,241,574
50,052,371
45,760,560
54,583,650
64,333,818
56,966,704
62,327,014
62,532,635
58,199,254
62,112,877
66,051,484
70,601,833
70,601,83366,051,48462,112,87758,199,25462,532,63562,327,01456,966,70464,333,81854,583,65045,760,56050,052,37142,241,57442,301,76744,033,89842,710,53542,653,85748,552,66636,566,90337,228,89034,671,60946,199,01739,830,82138,962,09436,157,35348,115,10539,420,01533,715,55632,082,36234,853,20130,731,19732,521,07530,860,31531,926,95528,572,06327,115,54927,631,25631,343,64927,565,90827,810,96532,162,84032,241,38029,473,38932,216,72131,063,368
       Other Current Assets 
954,149
513,627
1,312,817
409,896
1,253,584
903,858
1,767,643
663,150
1,775,523
600,759
1,950,672
1,086,786
2,927,488
402,519
2,168,658
538,482
1,700,633
411,317
1,997,436
1,315,806
3,123,620
594,874
2,351,964
501,538
1
0
-1
1,846,091
2,367,510
386,640
2,596,447
474,219
2,931,223
855,577
2,737,351
929,458
2,822,860
1,572,320
3,456,367
-1
-754,919
1,171,803
1
0
011,171,803-754,919-13,456,3671,572,3202,822,860929,4582,737,351855,5772,931,223474,2192,596,447386,6402,367,5101,846,091-101501,5382,351,964594,8743,123,6201,315,8061,997,436411,3171,700,633538,4822,168,658402,5192,927,4881,086,7861,950,672600,7591,775,523663,1501,767,643903,8581,253,584409,8961,312,817513,627954,149
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
186,015,238
197,995,248
202,032,343
205,984,256
204,502,058
209,663,746
211,766,527
217,937,558
215,083,355
246,522,139
247,209,415
249,202,757
253,690,443
257,253,297
255,258,886
246,266,241
248,618,620
255,559,315
257,818,158
298,705,307
298,705,307257,818,158255,559,315248,618,620246,266,241255,258,886257,253,297253,690,443249,202,757247,209,415246,522,139215,083,355217,937,558211,766,527209,663,746204,502,058205,984,256202,032,343197,995,248186,015,238000000000000000000000000
       Property Plant Equipment 
57,255,670
57,356,086
58,423,333
63,927,579
64,023,119
69,537,709
73,453,114
76,156,371
78,905,648
82,705,208
88,763,873
90,330,768
93,257,228
96,318,462
97,864,094
100,863,697
100,731,651
101,749,496
103,387,956
108,092,505
117,051,447
114,852,021
121,484,230
134,683,369
149,034,231
156,013,966
157,278,223
157,636,208
156,213,965
157,288,601
159,035,236
157,252,334
154,647,052
171,930,263
169,293,221
166,674,140
164,466,957
163,364,707
162,074,212
158,912,386
156,823,279
155,153,044
155,155,091
160,091,814
160,091,814155,155,091155,153,044156,823,279158,912,386162,074,212163,364,707164,466,957166,674,140169,293,221171,930,263154,647,052157,252,334159,035,236157,288,601156,213,965157,636,208157,278,223156,013,966149,034,231134,683,369121,484,230114,852,021117,051,447108,092,505103,387,956101,749,496100,731,651100,863,69797,864,09496,318,46293,257,22890,330,76888,763,87382,705,20878,905,64876,156,37173,453,11469,537,70964,023,11963,927,57958,423,33357,356,08657,255,670
       Goodwill 
1,987,983
1,987,983
1,987,983
1,758,250
1,758,250
1,758,250
1,758,250
1,758,250
1,758,250
1,758,250
1,758,250
1,758,250
1,758,250
1,758,250
1,758,250
0
0
0
227,496
245,565
245,565
245,565
245,565
245,565
245,565
245,565
0
245,565
245,565
245,565
245,565
245,565
245,565
11,890,881
11,254,286
11,548,861
11,548,861
11,548,861
11,548,861
11,328,045
11,328,045
0
0
7,254,091
7,254,0910011,328,04511,328,04511,548,86111,548,86111,548,86111,548,86111,254,28611,890,881245,565245,565245,565245,565245,565245,5650245,565245,565245,565245,565245,565245,565245,565227,4960001,758,2501,758,2501,758,2501,758,2501,758,2501,758,2501,758,2501,758,2501,758,2501,758,2501,758,2501,758,2501,987,9831,987,9831,987,983
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
973,060
1,022,521
1,334,503
2,588,700
2,969,361
2,995,436
4,418,795
5,628,419
5,689,622
6,045,871
10,567,638
11,755,859
14,520,087
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000014,520,08711,755,85910,567,6386,045,8715,689,6225,628,4194,418,7952,995,4362,969,3612,588,7001,334,5031,022,521973,060000000000000000
       Intangible Assets 
5,551,516
5,222,402
5,458,202
4,742,227
4,712,561
4,693,694
4,528,725
4,089,757
3,762,427
4,863,501
4,889,788
4,539,079
4,348,049
5,411,967
5,343,439
3,731,792
4,157,877
4,111,549
4,199,277
7,489,790
7,872,402
12,539,884
12,225,111
11,877,034
19,609,967
19,517,347
20,338,582
20,223,488
21,036,764
23,346,108
23,014,210
23,425,909
24,928,567
25,543,302
26,900,059
28,893,630
28,351,385
30,011,806
30,033,033
28,744,983
29,784,678
42,235,903
44,197,734
34,217,539
34,217,53944,197,73442,235,90329,784,67828,744,98330,033,03330,011,80628,351,38528,893,63026,900,05925,543,30224,928,56723,425,90923,014,21023,346,10821,036,76420,223,48820,338,58219,517,34719,609,96711,877,03412,225,11112,539,8847,872,4027,489,7904,199,2774,111,5494,157,8773,731,7925,343,4395,411,9674,348,0494,539,0794,889,7884,863,5013,762,4274,089,7574,528,7254,693,6944,712,5614,742,2275,458,2025,222,4025,551,516
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
1
0
1
0
0
-1
-1
1
0
0
0
0
-1
0
1
-1
-110-100001-1-1001011111000000000000000000000000
> Total Liabilities 
34,630,180
36,793,277
35,705,189
36,888,447
41,704,648
38,689,515
39,826,264
46,105,526
49,829,537
41,688,936
41,222,754
46,088,274
49,963,771
50,197,876
47,028,417
52,668,772
57,452,442
63,081,644
63,304,390
59,072,925
71,664,511
69,957,843
72,850,930
92,240,489
110,348,572
113,052,265
115,019,718
123,315,893
124,434,827
118,620,676
124,484,558
122,442,339
144,277,130
183,256,396
204,900,592
211,176,225
225,154,842
223,441,410
224,368,099
204,784,867
205,091,267
200,031,975
214,927,869
243,733,870
243,733,870214,927,869200,031,975205,091,267204,784,867224,368,099223,441,410225,154,842211,176,225204,900,592183,256,396144,277,130122,442,339124,484,558118,620,676124,434,827123,315,893115,019,718113,052,265110,348,57292,240,48972,850,93069,957,84371,664,51159,072,92563,304,39063,081,64457,452,44252,668,77247,028,41750,197,87649,963,77146,088,27441,222,75441,688,93649,829,53746,105,52639,826,26438,689,51541,704,64836,888,44735,705,18936,793,27734,630,180
   > Total Current Liabilities 
23,394,313
25,214,965
23,406,511
25,093,663
29,014,350
24,980,515
25,478,213
31,513,008
34,090,001
25,590,180
24,105,513
30,269,491
33,078,146
32,670,040
28,096,574
34,834,611
38,028,535
42,258,233
41,541,961
39,161,450
50,081,705
47,362,478
45,912,199
57,694,147
64,100,990
56,928,928
57,301,078
61,740,427
61,514,125
54,303,941
56,704,873
56,017,091
75,931,526
95,964,798
86,977,721
102,076,351
114,736,231
114,332,283
116,748,511
128,146,381
130,113,316
123,765,074
139,728,059
182,690,483
182,690,483139,728,059123,765,074130,113,316128,146,381116,748,511114,332,283114,736,231102,076,35186,977,72195,964,79875,931,52656,017,09156,704,87354,303,94161,514,12561,740,42757,301,07856,928,92864,100,99057,694,14745,912,19947,362,47850,081,70539,161,45041,541,96142,258,23338,028,53534,834,61128,096,57432,670,04033,078,14630,269,49124,105,51325,590,18034,090,00131,513,00825,478,21324,980,51529,014,35025,093,66323,406,51125,214,96523,394,313
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10,000,000
10,000,000
10,000,000
10,000,000
16,000,000
0
0
19,000,000
19,000,000
20,000,000
20,000,000
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000020,000,00020,000,00019,000,00019,000,0000016,000,00010,000,00010,000,00010,000,00010,000,00000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
10,000,000
10,000,000
10,000,000
10,000,000
16,000,000
0
0
19,000,000
19,000,000
20,000,000
20,000,000
20,000,000
20,000,000
20,000,000
21,500,000
36,500,000
45,534,958
45,656,780
51,365,071
49,768,556
51,902,409
51,930,230
62,052,434
62,064,954
62,300,404
72,839,705
109,453,855
109,453,85572,839,70562,300,40462,064,95462,052,43451,930,23051,902,40949,768,55651,365,07145,656,78045,534,95836,500,00021,500,00020,000,00020,000,00020,000,00020,000,00020,000,00019,000,00019,000,0000016,000,00010,000,00010,000,00010,000,00010,000,00000000000000000000
       Accounts payable 
3,598,154
5,756,904
3,614,585
5,741,776
5,690,236
3,156,611
3,775,440
3,206,482
2,883,372
2,873,007
2,817,369
5,483,747
6,305,528
6,253,159
3,423,858
4,783,419
5,614,374
4,643,989
4,438,883
4,195,962
7,343,474
5,971,565
5,456,589
6,864,014
7,422,860
7,903,505
9,025,008
8,935,576
8,846,632
7,376,926
10,056,960
10,686,622
8,343,745
19,060,943
13,793,490
17,221,945
21,043,920
22,341,448
21,085,943
19,582,928
19,017,802
20,076,083
25,834,986
20,909,853
20,909,85325,834,98620,076,08319,017,80219,582,92821,085,94322,341,44821,043,92017,221,94513,793,49019,060,9438,343,74510,686,62210,056,9607,376,9268,846,6328,935,5769,025,0087,903,5057,422,8606,864,0145,456,5895,971,5657,343,4744,195,9624,438,8834,643,9895,614,3744,783,4193,423,8586,253,1596,305,5285,483,7472,817,3692,873,0072,883,3723,206,4823,775,4403,156,6115,690,2365,741,7763,614,5855,756,9043,598,154
       Other Current Liabilities 
16,796,159
16,458,061
16,791,926
16,351,887
20,324,114
18,823,903
18,702,773
25,306,526
28,206,629
22,717,173
21,288,143
24,785,743
26,772,618
26,416,882
24,672,716
30,051,192
32,414,161
27,614,244
27,103,078
24,965,488
32,738,231
18,122,812
22,193,056
28,163,291
35,624,409
0
0
28,913,365
29,236,337
23,621,867
22,928,712
19,661,743
27,245,498
26,711,943
23,506,073
29,385,842
38,991,394
34,438,582
38,482,708
-1
1
35,752,709
0
1
1035,752,7091-138,482,70834,438,58238,991,39429,385,84223,506,07326,711,94327,245,49819,661,74322,928,71223,621,86729,236,33728,913,3650035,624,40928,163,29122,193,05618,122,81232,738,23124,965,48827,103,07827,614,24432,414,16130,051,19224,672,71626,416,88226,772,61824,785,74321,288,14322,717,17328,206,62925,306,52618,702,77318,823,90320,324,11416,351,88716,791,92616,458,06116,796,159
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
46,247,582
56,123,337
57,718,640
61,575,465
62,920,701
64,316,735
67,779,685
66,425,248
68,345,604
87,291,598
117,922,870
109,099,874
110,418,611
109,109,126
107,619,587
76,638,486
74,977,951
76,266,901
75,199,810
61,043,387
61,043,38775,199,81076,266,90174,977,95176,638,486107,619,587109,109,126110,418,611109,099,874117,922,87087,291,59868,345,60466,425,24867,779,68564,316,73562,920,70161,575,46557,718,64056,123,33746,247,582000000000000000000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
-10,000,000
-10,000,000
-10,000,000
-10,000,000
-16,000,000
0
0
-17,288,843
-17,444,790
-18,733,172
-18,834,950
969,879
1,164,137
2,654,569
2,478,083
2,581,143
3,427,567
3,130,844
2,978,545
2,856,954
2,728,182
2,564,399
2,305,211
2,087,557
2,413,744
2,371,026
2,021,075
2,021,0752,371,0262,413,7442,087,5572,305,2112,564,3992,728,1822,856,9542,978,5453,130,8443,427,5672,581,1432,478,0832,654,5691,164,137969,879-18,834,950-18,733,172-17,444,790-17,288,84300-16,000,000-10,000,000-10,000,000-10,000,000-10,000,00000000000000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
451,471
0
556,009
0
749,190
0
0
0
0
0
-1
0
0
0
0
0
0
0
0
0
000000000-100000749,1900556,0090451,471000000000000000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
5,591,552
5,958,229
6,213,216
6,299,589
6,434,266
6,181,277
6,467,868
6,294,982
6,798,523
7,959,624
8,133,395
0
9,046,054
10,121,272
10,866,284
10,974,964
11,808,504
13,597,331
14,440,481
15,179,996
14,977,149
14,986,632
15,150,972
15,840,044
0
0
0
0
0
0000015,840,04415,150,97214,986,63214,977,14915,179,99614,440,48113,597,33111,808,50410,974,96410,866,28410,121,2729,046,05408,133,3957,959,6246,798,5236,294,9826,467,8686,181,2776,434,2666,299,5896,213,2165,958,2295,591,552000000000000000
> Total Stockholder Equity
113,637,197
117,326,651
120,469,724
122,511,183
123,584,839
126,664,740
132,020,570
133,902,196
135,256,185
140,666,044
143,741,933
148,188,415
148,510,489
152,839,354
157,210,205
161,402,480
160,096,965
157,929,370
166,630,100
167,985,826
169,085,272
174,421,081
179,536,770
183,513,078
184,399,577
190,754,427
197,212,053
204,940,756
205,503,632
206,376,024
209,804,360
213,937,991
202,644,809
208,713,717
214,375,414
219,298,544
225,143,073
231,774,654
240,910,972
250,947,225
253,081,713
260,950,412
266,108,885
266,198,939
266,198,939266,108,885260,950,412253,081,713250,947,225240,910,972231,774,654225,143,073219,298,544214,375,414208,713,717202,644,809213,937,991209,804,360206,376,024205,503,632204,940,756197,212,053190,754,427184,399,577183,513,078179,536,770174,421,081169,085,272167,985,826166,630,100157,929,370160,096,965161,402,480157,210,205152,839,354148,510,489148,188,415143,741,933140,666,044135,256,185133,902,196132,020,570126,664,740123,584,839122,511,183120,469,724117,326,651113,637,197
   Common Stock
7,794,412
7,794,412
7,794,412
7,794,412
8,180,319
8,180,319
8,180,319
8,180,319
8,585,501
8,585,501
8,585,501
8,585,501
8,840,752
8,840,752
8,840,752
8,840,752
9,101,588
9,101,588
9,101,588
9,101,588
9,549,303
9,549,303
9,549,303
9,549,303
9,831,339
9,831,339
9,831,339
9,831,339
10,121,802
10,121,802
10,121,802
10,121,802
10,612,412
10,612,412
10,612,412
10,612,412
10,921,418
10,921,418
10,921,418
0
0
10,982,335
0
0
0010,982,3350010,921,41810,921,41810,921,41810,612,41210,612,41210,612,41210,612,41210,121,80210,121,80210,121,80210,121,8029,831,3399,831,3399,831,3399,831,3399,549,3039,549,3039,549,3039,549,3039,101,5889,101,5889,101,5889,101,5888,840,7528,840,7528,840,7528,840,7528,585,5018,585,5018,585,5018,585,5018,180,3198,180,3198,180,3198,180,3197,794,4127,794,4127,794,4127,794,412
   Retained Earnings Total Equity00000000000000000000000000000000000000000000
   Accumulated Other Comprehensive Income 00000000000000000000000000000000000000000000
   Capital Surplus 00000000000000000000000000000000000000000000
   Treasury Stock000000000000000000000-3,705,850-3,705,850-3,705,850-3,669,646-3,669,646-3,669,646-3,669,646-3,626,965-3,626,965-650,682-650,682-606,593-606,593-606,593-589,320-589,320-589,320-589,320-589,320-579,289-579,289-579,289-579,289
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
85,185
85,975
113,632
108,100
102,342
73,915
56,189
52,987
-21,032
-20,312
-19,473
-9,443
1,009,487
-228,129
632,257
564,521
2,875,120
2,923,710
3,520,327
2,924,347
3,221,086
2,745,639
2,188,175
1,866,245
0
0
1,272,187
0
0
001,272,187001,866,2452,188,1752,745,6393,221,0862,924,3473,520,3272,923,7102,875,120564,521632,257-228,1291,009,487-9,443-19,473-20,312-21,03252,98756,18973,915102,342108,100113,63285,97585,185000000000000000



Balance Sheet

Currency in KRW. All numbers in thousands.




Cash Flow

Currency in KRW. All numbers in thousands.




Income Statement

Currency in KRW. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue526,952,045
Cost of Revenue-269,704,720
Gross Profit257,247,325257,247,325
 
Operating Income (+$)
Gross Profit257,247,325
Operating Expense-494,719,247
Operating Income32,232,798-237,471,922
 
Operating Expense (+$)
Research Development9,009,804
Selling General Administrative103,435,369
Selling And Marketing Expenses0
Operating Expense494,719,247112,445,173
 
Net Interest Income (+$)
Interest Income1,279,247
Interest Expense-4,614,224
Other Finance Cost-0
Net Interest Income-3,334,977
 
Pretax Income (+$)
Operating Income32,232,798
Net Interest Income-3,334,977
Other Non-Operating Income Expenses0
Income Before Tax (EBT)25,830,19032,232,798
EBIT - interestExpense = -4,614,224
23,916,931
28,531,155
Interest Expense4,614,224
Earnings Before Interest and Taxes (EBIT)030,444,414
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax25,830,190
Tax Provision-2,366,929
Net Income From Continuing Ops23,463,26123,463,261
Net Income23,916,931
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net03,334,977
 

Technical Analysis of Daewon Pharm
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Daewon Pharm. The general trend of Daewon Pharm is BEARISH with 42.9% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Daewon Pharm's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-42.9%) Bearish trend (42.9%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Daewon Pharm.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 15,480 < 15,690 < 16,100.

The bearish price targets are: 13,940 > 13,530 > 13,530.

Tweet this
Daewon Pharm Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Daewon Pharm. The current mas is .

The long score for the Moving Averages is 4/14.
The longshort score for the Moving Averages is -6/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close > MA 20: The price is above the MA 20. +1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending up: The MA 50 is trending up. +1
  • Close > MA 50: The price is above the MA 50. +1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending up: The MA 200 is trending up. +1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Daewon Pharm Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Daewon Pharm. The current macd is 3.78317912.

The long score for the Moving Average Convergence/Divergence (MACD) is 4/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is 4/(-4 +4).

  • MACD line > signal line: The MACD line is above the signal line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Daewon Pharm price going up in the near term. +2
  • MACD > 0: The MACD is above the zero line (centerline), it indicates a bullish signal for Daewon Pharm. This means that the short-term moving average is higher than the long-term moving average, signaling positive momentum and suggesting a higher likelihood of the Daewon Pharm price continuing to rise in the near future. It indicates that buyers are gaining control, and there is optimism in the market, leading to potential price increases. +1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Daewon Pharm Daily Moving Average Convergence/Divergence (MACD) ChartDaewon Pharm Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Daewon Pharm. The current adx is 24.77.

The long score for the Directional Movement Index (DMI) is 2/7.
The longshort score for the Directional Movement Index (DMI) is 2/(-7 +7).

  • PLUS_ID > MINUS_DI: The +DI line is above the -DI line. This indicates a bullish signal in the market, as the positive directional movement is currently stronger than the negative directional movement, showing that buyers have the upper hand. Market psychology suggests that traders are optimistic, expecting further price increases, and are more willing to buy Daewon Pharm shares, leading to potential upward momentum in its price. +1
  • PLUS_ID > MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bullish trend could be forming. +1
Daewon Pharm Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Daewon Pharm. The current sar is 14,125.

The long score for the Parabolic SAR is 1/1.
The longshort score for the Parabolic SAR is 1/(-1 +1).

  • Close > SAR: The price is above the SAR. It's generally considered a bullish signal. +1
Daewon Pharm Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Daewon Pharm. The current rsi is 56.65. The current phase is Correction in bear market.

The long score for the Relative Strength Index (RSI) is 3/13.
The longshort score for the Relative Strength Index (RSI) is 2/(-13 +13).

  • Correction in bear market: Extended price decline in a downtrend, significant pullback. Consider reducing exposure, wait for signs of trend reversal.
  • Trending down: The RSI is trending down. -1
Daewon Pharm Daily Relative Strength Index (RSI) ChartDaewon Pharm Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Daewon Pharm. The current phase is Correction in bear market.

The long score for the Stochastic Oscillator is 1/6.
The longshort score for the Stochastic Oscillator is -2/(-6 +6).

  • STOCH > 50: The STOCH %K is above 50. There are more buyers than sellers. +1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Daewon Pharm price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
Daewon Pharm Daily Stochastic Oscillator ChartDaewon Pharm Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Daewon Pharm. The current cci is 67.55.

Daewon Pharm Daily Commodity Channel Index (CCI) ChartDaewon Pharm Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Daewon Pharm. The current cmo is 22.03.

The long score for the Chande Momentum Oscillator (CMO) is 1/1.
The longshort score for the Chande Momentum Oscillator (CMO) is 1/(-1 +1).

  • CMO > 0: The CMO is above 0, the momentum of the price is positive, indicating a potential uptrend in the price. +1
Daewon Pharm Daily Chande Momentum Oscillator (CMO) ChartDaewon Pharm Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Daewon Pharm. The current willr is -22.60273973.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Daewon Pharm is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Daewon Pharm Daily Williams %R ChartDaewon Pharm Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Daewon Pharm.

Daewon Pharm Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Daewon Pharm. The current atr is 346.93.

Daewon Pharm Daily Average True Range (ATR) ChartDaewon Pharm Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Daewon Pharm. The current obv is 18,870,900.

Daewon Pharm Daily On-Balance Volume (OBV) ChartDaewon Pharm Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Daewon Pharm. The current mfi is 64.07.

The long score for the Money Flow Index (MFI) is 1/2.
The longshort score for the Money Flow Index (MFI) is 1/(-2 +2).

  • MFI > 50: +1
Daewon Pharm Daily Money Flow Index (MFI) ChartDaewon Pharm Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Daewon Pharm.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-29MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2023-11-30MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2023-12-04STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-05CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-07MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-12CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2023-12-13STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-15STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-18STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-21DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-22STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-12-27STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-28SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-02MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-01-03WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-04STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-10MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-12WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-23MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-01-24STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-26MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-01-31SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-02STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-06STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-07STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-13CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-14DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-16STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-19DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2024-02-20DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-23SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-26CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-27MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-03-04MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-05DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI LONG ENTRY SHORT CLOSE80 crossover to upside
2024-03-06MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI SHORT ENTRY LONG CLOSE80 crossover to downside
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-11CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-14STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-15CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-22STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-28STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-29MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-04-04BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-16STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-17DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-04-18CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-04-19MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-23STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

Daewon Pharm Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Daewon Pharm based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5056.652
Ma 20Greater thanMa 5014,718.500
Ma 50Greater thanMa 10014,892.400
Ma 100Greater thanMa 20015,130.300
OpenGreater thanClose15,180.000
Total2/5 (40.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Daewon Pharm with someone you think should read this too:
  • Are you bullish or bearish on Daewon Pharm? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Daewon Pharm? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Daewon Pharm

I send you an email if I find something interesting about Daewon Pharm.


Comments

How you think about this?

Leave a comment

Stay informed about Daewon Pharm.

Receive notifications about Daewon Pharm in your mailbox!